Compounds > pyrimethamine
Page last updated: 2024-11-03

pyrimethamine and HIV Coinfection

pyrimethamine has been researched along with HIV Coinfection in 83 studies

Maloprim: contains above 2 cpds

Research Excerpts

ExcerptRelevanceReference
"To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV."9.27Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018)
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women."9.20Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. ( Abdulla, S; Aponte, J; Cot, M; Desai, M; Fernandes, S; González, R; Hanson, K; Katana, A; Kremsner, P; Kuwawenaruwa, A; Macete, E; Massougbodgi, A; Menéndez, C; Mombo-Ngoma, G; Ramharter, M; Sicuri, E; Slustker, L, 2015)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all pregnant women receive sulfadoxine-pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled antenatal care visit after 16 weeks of gestation."7.85Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region. ( Chi, BH; Kumwenda, A; Smid, M; Stoner, MC; Stringer, E; Stringer, JS; Vwalika, B, 2017)
"Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown."7.77Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011)
"Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTpSP) is one of the major strategies of malaria control in most African countries where malaria is endemic."7.77Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. ( Agomo, CO; Oyibo, WA, 2011)
"Prophylaxis of toxoplasmic encephalitis was performed with pyrimethamine in 6 patients with advanced HIV infection during combination therapy with protease inhibitors."7.72Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. ( Klinker, H; Langmann, P; Schirmer, D; Zilly, M, 2004)
"A fever case management (CM) approach using sulfadoxine-pyrimethamine (SP) was compared with two presumptive intertmittent SP treatment regimens in the second and third trimesters in pregnant primigravidae and secundigravidae in an area of intense Plasmodium falciparum malaria transmission in western Kenya."7.70Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. ( Ayisi, JG; Misore, A; Muga, R; Nahlen, BL; Oloo, AJ; Parise, ME; Roberts, JM; Schultz, LJ; Steketee, RW, 1998)
"The incidence of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) was analyzed in 83 human immunodeficiency virus (HIV)-infected patients who inhaled aerosolized pentamidine (AP) either for primary prophylaxis (group Ia) or secondary prophylaxis (group IIa) of PCP."7.68Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine. ( Gottschalk, J; Grünewald, T; Jautzke, G; Köppen, S; Pohle, HD; Ruf, B, 1992)
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas."5.41Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized ( Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021)
"Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae."5.39Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. ( Ali, D; Gutman, J; Mathanga, DP; Mwandama, D; Skarbinski, J; Wiegand, RE, 2013)
"To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV."5.27Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018)
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women."5.20Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. ( Abdulla, S; Aponte, J; Cot, M; Desai, M; Fernandes, S; González, R; Hanson, K; Katana, A; Kremsner, P; Kuwawenaruwa, A; Macete, E; Massougbodgi, A; Menéndez, C; Mombo-Ngoma, G; Ramharter, M; Sicuri, E; Slustker, L, 2015)
"Factors involved in the development of resistance to sulphadoxine-pyrimethamine (SP) by Plasmodium falciparum, particularly in the context of intermittent preventive treatment during pregnancy (IPTp), are not well known."5.15HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. ( Alonso, PL; Bardají, A; Cisteró, P; Dobaño, C; Mandomando, I; Mayor, A; Menéndez, C; Nhabomba, A; Sanz, S; Scahill, MD; Serra-Casas, E; Sigauque, B, 2011)
"Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in sub-Saharan Africa."5.14The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. ( Alonso, PL; Bardají, A; Chauhan, VS; Chitnis, CE; Dobaño, C; Jiménez, A; Mandomando, I; Mayor, A; Menéndez, C; Quintó, L; Serra-Casas, E; Sigauque, B, 2010)
"Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitemia and associated maternal anemia, premature delivery, and low birth weight."5.12Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. ( Filler, SJ; Hamel, M; Kazembe, P; Macheso, A; Newman, RD; Parise, ME; Steketee, RW; Thigpen, M, 2006)
"Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women."5.12Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ( Ayisi, JG; Green, MD; Kager, PA; Nahlen, BL; Nettey, H; Parise, ME; Steketee, R; van Eijk, AM; van Ter Kuile, FO, 2007)
"We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial."5.09Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. ( Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Grillo, R; Murri, R; Pallavicini, F; Pezzotti, P, 2001)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"We searched PubMed and EMBASE for randomised controlled trials (RCTs) and cohort studies on the effect of CPT on incidence of malaria and mortality in children and extracted data on the prevalence of sulphadoxine-pyrimethamine resistance-conferring point mutations."4.90Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. ( Davies, MA; Egger, M; Mbeye, NM; Phiri, KS; ter Kuile, FO; Wandeler, G, 2014)
"In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection."4.79Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997)
"Although the price increase of pyrimethamine in 2015 received heavy media coverage, there are little data regarding specific implications to hospitals and the total costs of treating inpatients with toxoplasmosis encephalitis (TE)."4.12Brief Report: Financial Burden of Toxoplasmosis Encephalitis Treatment at a Safety Net Hospital. ( Bogard, SN; Kempker, RR; Lee, JT; Patel, M, 2022)
" Interviews focused on perception of purpose of ANC pharmaceuticals (particularly iron supplements, sulfadoxine-pyrimethamine as intermittent prevention of malaria and antiretroviral therapy for HIV), beliefs regarding efficacy and risk, and understanding of dosage and regimen."3.96"They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali. ( Doumbia, SO; Hurley, EA; Searle, AR; Winch, PJ, 2020)
"In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all pregnant women receive sulfadoxine-pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled antenatal care visit after 16 weeks of gestation."3.85Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region. ( Chi, BH; Kumwenda, A; Smid, M; Stoner, MC; Stringer, E; Stringer, JS; Vwalika, B, 2017)
"Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown."3.77Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011)
"Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTpSP) is one of the major strategies of malaria control in most African countries where malaria is endemic."3.77Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. ( Agomo, CO; Oyibo, WA, 2011)
" They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days."3.76Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010)
"The anti-malarial agent chloroquine has activity against HIV."3.73Impact of chloroquine on viral load in breast milk. ( Aldrovandi, G; Ghosh, M; Kankasa, C; Kasonde, P; Kuhn, L; Semrau, K; Shutes, E; Sinkala, M; Thea, DM; Vwalika, C, 2006)
"Febrile adults with Plasmodium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days."3.73HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. ( Bloland, PB; Hamel, MJ; Kain, KC; Obonyo, CO; Shah, SN; Slutsker, L; Smith, EE, 2006)
"Prophylaxis of toxoplasmic encephalitis was performed with pyrimethamine in 6 patients with advanced HIV infection during combination therapy with protease inhibitors."3.72Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. ( Klinker, H; Langmann, P; Schirmer, D; Zilly, M, 2004)
"A fever case management (CM) approach using sulfadoxine-pyrimethamine (SP) was compared with two presumptive intertmittent SP treatment regimens in the second and third trimesters in pregnant primigravidae and secundigravidae in an area of intense Plasmodium falciparum malaria transmission in western Kenya."3.70Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. ( Ayisi, JG; Misore, A; Muga, R; Nahlen, BL; Oloo, AJ; Parise, ME; Roberts, JM; Schultz, LJ; Steketee, RW, 1998)
"The incidence of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) was analyzed in 83 human immunodeficiency virus (HIV)-infected patients who inhaled aerosolized pentamidine (AP) either for primary prophylaxis (group Ia) or secondary prophylaxis (group IIa) of PCP."3.68Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine. ( Gottschalk, J; Grünewald, T; Jautzke, G; Köppen, S; Pohle, HD; Ruf, B, 1992)
"Pyrimethamine treatment did not result in a reduction in the size of the inducible reservoir."3.30The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy. ( Bax, HI; Burger, D; Colbers, A; Crespo, R; de Mendonça Melo, M; de Vries-Sluijs, TEMS; Gruters, RA; Hossain, T; Kan, TW; Katsikis, PD; Koch, BCP; Li, L; Lungu, C; Mahmoudi, T; Mesplède, T; Mueller, YM; Nouwen, JL; Overmars, RJ; Palstra, RJ; Papageorgiou, G; Prins, HAB; Rao, S; Rijnders, BJA; Rokx, C; Schurink, CAM; Stoszko, M; van de Vijver, DAMC; van Gorp, ECM; van Kampen, JJA; van Nood, E; Verbon, A, 2023)
"Malaria is an infectious disease which disproportionately effects children and pregnant women."2.72Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. ( Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021)
"Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and pharmacokinetic profiles were determined after administration of the last dose."2.68Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ( Davidian, M; Hafner, R; Jacobson, JM; Luft, BJ; Raasch, RH; Rainey, PM, 1996)
"To identify risk factors for cerebral toxoplasmosis (CT) in HIV patients (pts) with positive serology for Toxoplasma gondii and CD4 < 200/mm3, data from the placebo group (N = 280) of a primary prophylaxis trial, were analyzed."2.67[Risk factors of cerebral toxoplasmosis in patients with HIV infection: data of a primary prevention trial]. ( Aubertin, J; Chene, G; Hafner, R; Leport, C; Luft, B; Morlat, P; Pueyo, S; Salamon, R; Vilde, JL, 1993)
"11), and drug discontinuation because of adverse events (P-C: RR 0."2.55A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? ( Benites-Zapata, VA; Deshpande, A; Hernandez, AV; Pasupuleti, V; Pellegrino, D; Penalva de Oliveira, AC; Thota, P; Vidal, JE, 2017)
"Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity."2.50Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014)
"Although Pneumocystis carinii pneumonia (PCP) can occur in any patient with severe impairment of immunity, there has been a sharp rise in incidence with the spread of human immunodeficiency virus through the USA and Western Europe, where nearly 80% of patients with HIV infection have at least one episode of PCP during their lifetime (Murray et al, 1984)."2.38Prophylaxis and treatment of Pneumocystis carinii pneumonia. ( Bateman, NT; O'Doherty, MJ, 1991)
"Various oral medicines have shown phototoxicity therefore, we aimed to study the phototoxicity of PYR and its molecular mechanism involving stress responsive lysosomal protein Lamp2 and mitochondrial mediated signaling pathway under normal UVA/B exposure."1.72Pyrimethamine induces phototoxicity in human keratinocytes via lysosomal and mitochondrial dependent signaling pathways under environmental UVA and UVB exposure. ( Yadav, N, 2022)
"Malaria is a leading cause of morbidity and mortality among HIV-infected pregnant women in sub-Saharan Africa: at least 1 million pregnancies among HIV-infected women are complicated by co-infection with malaria annually, leading to increased risk of premature delivery, severe anaemia, delivery of low birth weight infants, and maternal death."1.46Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa. ( Bendavid, E; Brandeau, ML; Choi, SE, 2017)
"Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae."1.39Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. ( Ali, D; Gutman, J; Mathanga, DP; Mwandama, D; Skarbinski, J; Wiegand, RE, 2013)
"Sulfadoxine-pyrimethamine has been widely used as first-line therapy for uncomplicated malaria throughout sub-Saharan Africa."1.33Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. ( Barnwell, JW; Bloland, P; Escalante, AA; Hamel, M; Huber, C; McCollum, AM; Ouma, P; Poe, AC; Shi, YP; Slutsker, L; Udhayakumar, V; Vulule, J; Zhou, Z, 2006)
" If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators."1.29The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. ( Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ, 1995)
"ET was the AIDS-defining condition in 44% of the patients."1.29[Cerebral toxoplasmosis in patients with human immunodeficiency virus (HIV) infection. Clinico-radiological and therapeutic aspects in 63 patients]. ( Barrio, JL; Cadafalch, J; Domingo, P; Ferrer, S; Fuentes, I; Fuster, M; Iranzo, A; Muñoz, C; Nolla, J; Ris, J; Sambeat, MA, 1996)
"18 for the 50-mg/day and 25-mg/day dosage of pyrimethamine, respectively."1.28Ocular toxoplasmosis in human immunodeficiency virus-infected patients. ( Cochereau-Massin, I; Girard, B; Katlama, C; Lautier-Frau, M; LeHoang, P; Leport, C; Marcel, P; Robinet, M; Zazoun, L; Zerdoun, E, 1992)

Research

Studies (83)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's27 (32.53)18.2507
2000's22 (26.51)29.6817
2010's24 (28.92)24.3611
2020's10 (12.05)2.80

Authors

AuthorsStudies
Kabuya, JB1
Ippolito, MM1
Sikalima, J1
Tende, C1
Champo, D1
Mwakazanga, D1
Young, AMP1
Mulenga, M3
Chongwe, G1
Manyando, C1
Prosty, C1
Hanula, R1
Levin, Y1
Bogoch, II1
McDonald, EG1
Lee, TC1
Yadav, N1
Bogard, SN1
Lee, JT1
Patel, M1
Kempker, RR1
Ondriska, F1
Soják, Ľ1
Boldiš, V1
Piesecká, Ľ1
Mikula, P1
Kováč, Ľ1
Prins, HAB1
Crespo, R1
Lungu, C1
Rao, S1
Li, L1
Overmars, RJ1
Papageorgiou, G1
Mueller, YM1
Stoszko, M1
Hossain, T1
Kan, TW1
Rijnders, BJA1
Bax, HI1
van Gorp, ECM1
Nouwen, JL1
de Vries-Sluijs, TEMS1
Schurink, CAM1
de Mendonça Melo, M1
van Nood, E1
Colbers, A1
Burger, D1
Palstra, RJ1
van Kampen, JJA1
van de Vijver, DAMC1
Mesplède, T1
Katsikis, PD1
Gruters, RA1
Koch, BCP1
Verbon, A1
Mahmoudi, T1
Rokx, C1
Searle, AR1
Hurley, EA1
Doumbia, SO1
Winch, PJ1
Li, Y1
Zeng, YM1
Lu, YQ1
Qin, YY1
Chen, YK1
Hughes, E1
Wallender, E1
Mohamed Ali, A1
Jagannathan, P1
Savic, RM1
Manirakiza, A2
Tondeur, L1
Ketta, MYB1
Sepou, A2
Serdouma, E2
Gondje, S2
Bata, GGB1
Boulay, A2
Moyen, JM2
Sakanga, O2
Le-Fouler, L2
Kazanji, M2
Briand, V2
Lombart, JP1
Vray, M2
Choi, SE1
Brandeau, ML1
Bendavid, E1
González, R2
Pons-Duran, C1
Piqueras, M1
Aponte, JJ1
Ter Kuile, FO2
Menéndez, C6
Akinyotu, O1
Bello, F1
Abdus-Salam, R1
Arowojolu, A1
Amimo, F1
Moon, TD1
Magit, A1
Sacarlal, J1
Lambert, B1
Nomura, S1
Juma, DW1
Muiruri, P1
Yuhas, K1
John-Stewart, G1
Ottichilo, R1
Waitumbi, J1
Singa, B1
Polyak, C1
Kamau, E1
Gutman, J2
Mwandama, D1
Wiegand, RE1
Ali, D1
Mathanga, DP1
Skarbinski, J1
Bata, GG1
Moussa, S1
Klement, E1
Pitché, P1
Kendjo, E1
Singo, A1
D'Almeida, S1
Akouete, F1
Akpaloo, Y1
Tossa, K1
Prince-Agbodjan, S1
Patassi, A1
Caumes, E1
Moya-Alvarez, V1
Abellana, R1
Cot, M4
Mbeye, NM1
Davies, MA1
Phiri, KS1
Egger, M1
Wandeler, G1
Sicuri, E1
Fernandes, S1
Macete, E1
Mombo-Ngoma, G1
Massougbodgi, A1
Abdulla, S1
Kuwawenaruwa, A1
Katana, A1
Desai, M1
Ramharter, M1
Kremsner, P1
Slustker, L1
Aponte, J2
Hanson, K1
Ibitokou, SA1
Denoeud-Ndam, L1
Ezinmegnon, S1
Ladékpo, R1
Zannou, DM1
Massougbodji, A2
Girard, PM2
Luty, AJ1
Ndam, NT1
Ferenchick, E1
Roman, E1
Bardají, A4
Mangiaterra, V1
Hernandez, AV1
Thota, P1
Pellegrino, D1
Pasupuleti, V1
Benites-Zapata, VA1
Deshpande, A1
Penalva de Oliveira, AC1
Vidal, JE1
Stoner, MC1
Vwalika, B1
Smid, M1
Kumwenda, A1
Stringer, E1
Chi, BH1
Stringer, JS1
Slutsker, L3
Naniche, D1
Lahuerta, M1
Sigauque, B3
Romagosa, C1
Berenguera, A1
Mandomando, I3
David, C1
Sanz, S2
Ordi, J1
Alonso, P1
Ochong, E1
Bell, DJ1
Johnson, DJ1
D'Alessandro, U2
Muangnoicharoen, S1
Van Geertruyden, JP2
Winstanley, PA1
Bray, PG1
Ward, SA1
Owen, A1
Newman, PM1
Wanzira, H1
Tumwine, G1
Arinaitwe, E1
Waldman, S1
Achan, J1
Havlir, D1
Rosenthal, PJ2
Dorsey, G2
Clark, TD1
Cohan, D1
Serra-Casas, E2
Quintó, L1
Dobaño, C2
Jiménez, A1
Chauhan, VS1
Chitnis, CE1
Alonso, PL2
Mayor, A2
Oyibo, WA1
Agomo, CO1
Scahill, MD1
Nhabomba, A1
Cisteró, P1
Kapito-Tembo, A1
Meshnick, SR2
van Hensbroek, MB1
Phiri, K1
Fitzgerald, M1
Mwapasa, V2
Le Port, A1
Cottrell, G1
Dechavanne, C1
Bouraima, A1
Guerra, J1
Choudat, I1
Fayomi, B1
Migot-Nabias, F1
Garcia, A1
Kiderlen, TR1
Liesenfeld, O1
Schürmann, D2
Schneider, T1
Kiyingi, HS1
Egwang, TG1
Nannyonga, M1
Allinson, J1
Topping, W1
Edwards, SG1
Miller, RF1
Anghel, G1
Nahimana, A2
Rabodonirina, M2
Zanetti, G1
Meneau, I1
Francioli, P2
Bille, J2
Hauser, PM2
Langmann, P1
Schirmer, D1
Zilly, M1
Klinker, H1
Bachmeyer, C1
Mouchnino, G1
Thulliez, P1
Blum, L1
Semrau, K1
Kuhn, L1
Kasonde, P1
Sinkala, M1
Kankasa, C1
Shutes, E1
Vwalika, C1
Ghosh, M1
Aldrovandi, G1
Thea, DM1
McCollum, AM1
Poe, AC1
Hamel, M2
Huber, C1
Zhou, Z1
Shi, YP2
Ouma, P1
Vulule, J1
Bloland, P1
Barnwell, JW1
Udhayakumar, V1
Escalante, AA1
Rogerson, SJ1
Filler, SJ1
Kazembe, P1
Thigpen, M1
Macheso, A1
Parise, ME3
Newman, RD1
Steketee, RW2
Mwananyanda, L1
Chalwe, V1
Moerman, F1
Chilengi, R1
Kasongo, W1
Van Overmeir, C1
Dujardin, JC1
Colebunders, R1
Kestens, L1
Laufer, MK2
Plowe, CV2
Malamba, SS1
Mermin, J1
Reingold, A1
Lule, JR1
Downing, R1
Ransom, R1
Kigozi, A1
Hunt, BM1
Hubbard, A1
Shah, SN1
Smith, EE1
Obonyo, CO1
Kain, KC1
Bloland, PB1
Hamel, MJ1
Brouwer, KC1
Mirel, LB1
Yang, C1
Lal, RB1
Kolczak, MS1
Van Eijk, AM2
Ayisi, J1
Otieno, JA1
Nahlen, BL3
Steketee, R2
Lal, AA1
Green, MD1
van Ter Kuile, FO1
Ayisi, JG2
Kager, PA1
Nettey, H1
van Oosterhout, JJ1
Thesing, PC1
Dzinjalamala, FK1
Hsi, T1
Beraho, L1
Graham, SM1
Taylor, TE1
Opravil, M3
Pechère, M1
Lazzarin, A1
Heald, A1
Rüttimann, S1
Iten, A1
Furrer, H1
Oertle, D1
Praz, G1
Vuitton, DA1
Bouboulis, DA1
Rubinstein, A1
Shliozberg, J1
Madden, J1
Frieri, M1
Belda Mira, A1
Rovira Daudí, E1
Díaz Sánchez, F1
Michavila Gómez, J1
Pueyo, S2
Leport, C4
Chene, G3
Morlat, P3
Hafner, R5
Vilde, JL3
Luft, B2
Salamon, R3
Aubertin, J3
Rousseau, F2
Joos, B1
Lüthy, R1
Jacobson, MA1
Besch, CL1
Child, C1
Matts, JP1
Muth, K1
Wentworth, DN1
Neaton, JD1
Abrams, D1
Rimland, D1
Mallolas, J1
Zamora, L1
Gatell, JM1
Miró, JM1
Vernet, E1
Valls, ME1
Soriano, E1
SanMiguel, JG1
Landman, R1
Gaudebout, C2
Olivares, R1
Saimot, AG1
Jelazko, P1
Certain, A1
Boué, F1
Bouvet, E1
Podzamczer, D1
Santín, M1
Jimenez, J1
Casanova, A1
Bolao, F1
Gudiol, GR1
Alba, D1
Molina, F1
Ripoll, MM1
del Arco, A1
Piketty, C1
Weiss, L1
Picard-Dahan, C1
Fegueux, S1
Belaich, S1
Kazatchkine, MD1
Ferrer, S1
Fuentes, I1
Domingo, P1
Muñoz, C1
Iranzo, A1
Barrio, JL1
Fuster, M1
Ris, J1
Sambeat, MA1
Cadafalch, J1
Nolla, J1
DeMets, DL1
Fleming, TR1
Whitley, RJ1
Childress, JF1
Ellenberg, SS1
Foulkes, M1
Mayer, KH1
O'Fallon, J1
Pollard, RB1
Rahal, JJ1
Jacobson, JM1
Davidian, M1
Rainey, PM1
Raasch, RH1
Luft, BJ2
Ebrahimzadeh, A1
Bottone, EJ1
Miro, J1
Bucher, HC1
Griffith, L1
Guyatt, GH1
Hoetelmans, RM1
Kraaijeveld, CL1
Meenhorst, PL1
Mulder, JW1
Burger, DM1
Koks, CH1
Beijnen, JH1
Schmidt-Westhausen, A1
Grünewald, T3
Reichart, PA1
Pohle, HD2
Schultz, LJ1
Roberts, JM1
Misore, A1
Muga, R1
Oloo, AJ1
Murri, R2
Ammassari, A1
Pezzotti, P1
Cingolani, A1
De Luca, A2
Pallavicini, F1
Grillo, R1
Antinori, A2
Lightman, S1
Lynn, WA1
Bergmann, F1
Albrecht, H1
Padberg, J1
Wünsche, T1
Schürmann, M1
Grobusch, M1
Vallée, M1
Ruf, B2
Suttorp, N1
Cochereau-Massin, I1
LeHoang, P1
Lautier-Frau, M1
Zerdoun, E1
Zazoun, L1
Robinet, M1
Marcel, P1
Girard, B1
Katlama, C1
Tamburrini, E1
Ortona, L1
Köppen, S1
Jautzke, G1
Gottschalk, J1
O'Doherty, MJ1
Bateman, NT1
Clotet, B1
Sirera, G1
Romeu, J1
Gimeno, JM1
Jou, A1
Condom, MJ1
Tor, J1
Foz, M1
Lucey, DR1
Lucey, CR1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444]Phase 1142 participants (Actual)Interventional2015-09-30Completed
Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial[NCT01425073]500 participants (Actual)Interventional2012-02-29Completed
Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study)[NCT01746199]Phase 3193 participants (Actual)Interventional2013-12-31Completed
Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy[NCT00811421]5,820 participants (Actual)Interventional2009-09-30Completed
Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781]1,028 participants Interventional2003-08-31Active, not recruiting
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167]Phase 42,500 participants (Anticipated)Interventional2023-11-06Recruiting
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390]Phase 270 participants (Actual)Interventional2009-03-31Completed
Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi[NCT00126906]700 participants Interventional2002-10-31Completed
Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia[NCT00304980]3,000 participants Interventional2003-03-31Terminated
A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection[NCT00000666]600 participants InterventionalCompleted
Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii[NCT00000973]Phase 126 participants InterventionalCompleted
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients[NCT00000643]Phase 2150 participants InterventionalCompleted
Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850]Phase 32,793 participants (Actual)Interventional2009-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants-0.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-1.2

Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C

The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants10.8
C: Chloroquine Then Placebo for On-ART Participants-2.4

Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period

For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants-2.0
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-3.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24

The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24

Interventionpercent of CD8 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants5.5
B: Placebo Then Chloroquine for Off-ART Participants1.5
C: Chloroquine Then Placebo for On-ART Participants-0.1
D: Placebo Then Chloroquine for On-ART Participants-2.9

Change in Total CD4 T Cell Count From Baseline to Week 12

Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12

Interventioncells/mm^3 (Median)
A: Chloroquine Then Placebo for Off-ART Participants-27
B: Placebo Then Chloroquine for Off-ART Participants-11
C: Chloroquine Then Placebo for On-ART Participants-6
D: Placebo Then Chloroquine for On-ART Participants7

Fasting Lipopolysaccharides (LPS) at Entry

Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants13.68
B: Placebo Then Chloroquine for Off-ART Participants1.64
C: Chloroquine Then Placebo for On-ART Participants8.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 12

Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants14.37
B: Placebo Then Chloroquine for Off-ART Participants13.06
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants7.00

Fasting Lipopolysaccharides (LPS) at Week 24

Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24

Interventionpg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants20.54
B: Placebo Then Chloroquine for Off-ART Participants2.83
C: Chloroquine Then Placebo for On-ART Participants7.00
D: Placebo Then Chloroquine for On-ART Participants8.00

HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry

Interventionlog10 copies/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants4.48
B: Placebo Then Chloroquine for Off-ART Participants4.42

Number of Participants With Events Grade 3 or Higher

Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28

Interventionparticipants (Number)
A: Chloroquine Then Placebo for Off-ART Participants0
B: Placebo Then Chloroquine for Off-ART Participants1
C: Chloroquine Then Placebo for On-ART Participants1
D: Placebo Then Chloroquine for On-ART Participants0

Percent CD4 HLA-DR+/CD38+ at Baseline

Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants8.5
B: Placebo Then Chloroquine for Off-ART Participants9.8
C: Chloroquine Then Placebo for On-ART Participants8.7
D: Placebo Then Chloroquine for On-ART Participants9.9

Percent CD4 HLA-DR+/CD38+ at Week 12

Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants6.5
B: Placebo Then Chloroquine for Off-ART Participants10.5
C: Chloroquine Then Placebo for On-ART Participants7.7
D: Placebo Then Chloroquine for On-ART Participants9.0

Percent CD4 HLA-DR+/CD38+ at Week 24

Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD4 expressing HLA-DR+/CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants11.0
B: Placebo Then Chloroquine for Off-ART Participants12.5
C: Chloroquine Then Placebo for On-ART Participants7.3
D: Placebo Then Chloroquine for On-ART Participants9.2

Percent CD8 CD38+ at Baseline

Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.0
B: Placebo Then Chloroquine for Off-ART Participants77.0
C: Chloroquine Then Placebo for On-ART Participants50.8
D: Placebo Then Chloroquine for On-ART Participants49.9

Percent CD8 CD38+ at Week 12

Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants71.5
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.9
D: Placebo Then Chloroquine for On-ART Participants51.9

Percent CD8 CD38+ at Week 24

Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24

Interventionpercent of CD8 expressing CD38+ (Median)
A: Chloroquine Then Placebo for Off-ART Participants78.0
B: Placebo Then Chloroquine for Off-ART Participants79.5
C: Chloroquine Then Placebo for On-ART Participants50.6
D: Placebo Then Chloroquine for On-ART Participants48.7

Soluble CD14 (sCD14) at Baseline

Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.43
B: Placebo Then Chloroquine for Off-ART Participants1.97
C: Chloroquine Then Placebo for On-ART Participants1.80
D: Placebo Then Chloroquine for On-ART Participants1.58

Soluble CD14 (sCD14) at Week 12

Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants1.88
C: Chloroquine Then Placebo for On-ART Participants2.04
D: Placebo Then Chloroquine for On-ART Participants1.63

Soluble CD14 (sCD14) at Week 24

Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24

Interventionmillion pg/mL (Median)
A: Chloroquine Then Placebo for Off-ART Participants1.53
B: Placebo Then Chloroquine for Off-ART Participants2.19
C: Chloroquine Then Placebo for On-ART Participants1.77
D: Placebo Then Chloroquine for On-ART Participants1.72

HIV-1 RNA Copies/mL at Study Entry for On-ART Participants

Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants162
D: Placebo Then Chloroquine for On-ART Participants172

HIV-1 RNA Copies/mL at Week 12 for On-ART Participants

Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants161
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Week 24 for On-ART Participants

Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24

,
Interventionparticipants (Number)
at or below lower limit of quantitationabove lower limit of quantitation
C: Chloroquine Then Placebo for On-ART Participants142
D: Placebo Then Chloroquine for On-ART Participants181

HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants

Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24

,
Interventionlog10 copies/mL (Median)
Week 12Week 24
A: Chloroquine Then Placebo for Off-ART Participants4.684.69
B: Placebo Then Chloroquine for Off-ART Participants4.284.61

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline

Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.651228.66286390
B: Placebo Then Chloroquine for Off-ART Participants1.621377.81328460
C: Chloroquine Then Placebo for On-ART Participants1.011316.63107890
D: Placebo Then Chloroquine for On-ART Participants1.511250.85103530

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12

Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.681209.50251320
B: Placebo Then Chloroquine for Off-ART Participants1.281347.06319770
C: Chloroquine Then Placebo for On-ART Participants1.151441.35126540
D: Placebo Then Chloroquine for On-ART Participants1.301304.77117890

IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24

Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpg/mL (Median)
IL-6sTNF-rID-dimer
A: Chloroquine Then Placebo for Off-ART Participants1.341327.21264240
B: Placebo Then Chloroquine for Off-ART Participants1.181420.30294780
C: Chloroquine Then Placebo for On-ART Participants1.021230.21100860
D: Placebo Then Chloroquine for On-ART Participants1.271176.20124920

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline

Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0345.489.122.521.0438.6096.299.82
B: Placebo Then Chloroquine for Off-ART Participants0.0336.159.356.130.8339.9497.5216.37
C: Chloroquine Then Placebo for On-ART Participants0.1319.9110.964.481.3148.1796.114.58
D: Placebo Then Chloroquine for On-ART Participants0.0723.6512.666.491.1726.0895.388.28

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12

Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0051.907.663.740.8443.5197.9015.03
B: Placebo Then Chloroquine for Off-ART Participants0.0540.498.488.431.0336.4797.1816.32
C: Chloroquine Then Placebo for On-ART Participants0.1014.7013.937.241.4747.8395.407.10
D: Placebo Then Chloroquine for On-ART Participants0.1418.2013.645.161.0126.7595.156.09

Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24

Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24

,,,
Interventionpercentage of cells (Median)
%pDC expressing CD80+%pDC expressing CD83+%pDC expressing CD86+%pDC expressing PDL-1+%mDC expressing CD80+%mDC expressing CD83+%mDC expressing CD86+%mDC expressing PDL-1+
A: Chloroquine Then Placebo for Off-ART Participants0.0544.5010.134.340.9441.2197.709.53
B: Placebo Then Chloroquine for Off-ART Participants0.0038.967.897.451.1233.1997.0514.84
C: Chloroquine Then Placebo for On-ART Participants0.0814.8011.795.630.7636.6596.694.13
D: Placebo Then Chloroquine for On-ART Participants0.1617.6512.886.521.3924.1492.417.49

Reviews

8 reviews available for pyrimethamine and HIV Coinfection

ArticleYear
Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Encephalitis; HIV Infections; Humans; Pyrimethamine; Toxoplasmosis, Cerebral; Trimethoprim, Sulfamet

2023
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:4

    Topics: Amodiaquine; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins

2021
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 03-21, Volume: 3

    Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug

2018
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
    Malaria journal, 2014, Jul-11, Volume: 13

    Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental

2014
Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis.
    Tropical medicine & international health : TM & IH, 2014, Volume: 19, Issue:9

    Topics: Africa South of the Sahara; Antimalarials; Child; Drug Combinations; Drug Resistance; HIV Infections

2014
A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?
    HIV medicine, 2017, Volume: 18, Issue:2

    Topics: Adult; Antiprotozoal Agents; Clindamycin; Cohort Studies; Female; HIV Infections; Humans; Male; Midd

2017
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, Jun-01, Volume: 15, Issue:2

    Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal

1997
Prophylaxis and treatment of Pneumocystis carinii pneumonia.
    British journal of hospital medicine, 1991, Volume: 45, Issue:5

    Topics: Antimalarials; CD4-Positive T-Lymphocytes; Clinical Protocols; Dapsone; Drug Combinations; HIV Infec

1991

Trials

29 trials available for pyrimethamine and HIV Coinfection

ArticleYear
Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized
    Trials, 2021, Nov-20, Volume: 22, Issue:1

    Topics: Antimalarials; Artemisinins; Clinical Trials, Phase III as Topic; Diagnostic Tests, Routine; Drug Co

2021
The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.
    Science advances, 2023, 03-17, Volume: 9, Issue:11

    Topics: CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Pyrimethamine; RNA; Valproic Acid; Virus

2023
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections.
    Medicine, 2020, Volume: 99, Issue:20

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-I

2020
Cotrimoxazole versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in HIV-infected pregnant women in Bangui, Central African Republic: A pragmatic randomised controlled trial.
    Tropical medicine & international health : TM & IH, 2021, Volume: 26, Issue:10

    Topics: Adult; Antimalarials; Central African Republic; Drug Combinations; Female; HIV Infections; Humans; M

2021
Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2018, Volume: 142, Issue:2

    Topics: Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Mefloquine; Nigeri

2018
The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.
    PLoS neglected tropical diseases, 2019, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Foli

2019
Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA).
    Trials, 2013, Aug-14, Volume: 14

    Topics: Antimalarials; Central African Republic; Clinical Protocols; Coinfection; Drug Administration Schedu

2013
Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Incidence; Mala

2014
Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Antimalarials; Cost-Benefit Analysis; Drug Combinations; Female; HIV Infections; Humans; Kenya; Mala

2015
Insights Into Circulating Cytokine Dynamics During Pregnancy in HIV-Infected Beninese Exposed to Plasmodium falciparum Malaria.
    The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:2

    Topics: Adult; Antimalarials; Benin; Drug Combinations; Female; HIV Infections; Humans; Interleukin-10; Inte

2015
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV

2008
The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes.
    The Journal of infectious diseases, 2010, Jan-01, Volume: 201, Issue:1

    Topics: Antibodies, Protozoan; Antimalarials; Chemoprevention; Drug Administration Schedule; Drug Combinatio

2010
HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Alleles; Antimalarials; Chemoprevention; DNA, Protozoan; Drug Combinations; Drug Resistance;

2011
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:2

    Topics: Adult; Antimalarials; Benin; Chloroquine; Drug Combinations; Female; Health Policy; HIV Infections;

2011
Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi.
    The Journal of infectious diseases, 2006, Aug-01, Volume: 194, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; HIV Infec

2006
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.
    The Journal of infectious diseases, 2006, Oct-01, Volume: 194, Issue:7

    Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; CD4 Lymphocyte Count; Drug Comb

2006
Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya.
    The Journal of infectious diseases, 2007, Nov-01, Volume: 196, Issue:9

    Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Drug Combinations; Female; Half-Life; HIV Infect

2007
Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 20, Issue:2

    Topics: Adult; CD4 Lymphocyte Count; Dapsone; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma

1995
[Risk factors of cerebral toxoplasmosis in patients with HIV infection: data of a primary prevention trial].
    La Revue de medecine interne, 1993, Volume: 14, Issue:10

    Topics: Double-Blind Method; HIV Infections; HIV-1; Humans; Pyrimethamine; Risk Factors; Toxoplasmosis, Cere

1993
[Primary prevention of cerebral toxoplasmosis in patients with HIV infection: results of a double-blind randomized trial, pyrimethamine versus placebo].
    La Revue de medecine interne, 1993, Volume: 14, Issue:10

    Topics: Double-Blind Method; HIV Infections; HIV-1; Humans; Placebos; Pyrimethamine; Toxoplasmosis, Cerebral

1993
Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:2

    Topics: Adult; AIDS-Related Opportunistic Infections; Double-Blind Method; Female; HIV Infections; Humans; M

1994
Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    AIDS (London, England), 1993, Volume: 7, Issue:1

    Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Drug Therapy, Co

1993
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    The New England journal of medicine, 1993, May-27, Volume: 328, Issue:21

    Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence

1993
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
    AIDS (London, England), 1993, Volume: 7, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Therapy, C

1993
Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:6

    Topics: AIDS-Related Opportunistic Infections; Drug Interactions; Half-Life; HIV Infections; Humans; Male; P

1996
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:3

    Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Disease Progression; Double-Blind Metho

1997
Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
    Journal of acquired immune deficiency syndromes (1999), 2001, May-01, Volume: 27, Issue:1

    Topics: Adult; Animals; Anti-Infective Agents; Bacterial Infections; Dapsone; Encephalitis; Female; HIV Infe

2001
Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2002, Volume: 21, Issue:5

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Antiretroviral T

2002
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia.
    Lancet (London, England), 1992, Sep-26, Volume: 340, Issue:8822

    Topics: Dapsone; Drug Therapy, Combination; HIV Infections; Humans; Pneumonia, Pneumocystis; Pyrimethamine;

1992

Other Studies

46 other studies available for pyrimethamine and HIV Coinfection

ArticleYear
Pyrimethamine induces phototoxicity in human keratinocytes via lysosomal and mitochondrial dependent signaling pathways under environmental UVA and UVB exposure.
    Toxicology, 2022, Volume: 479

    Topics: Dermatitis, Phototoxic; HIV Infections; Humans; Keratinocytes; Lysosomes; Phosphatidylserines; Pyrim

2022
Brief Report: Financial Burden of Toxoplasmosis Encephalitis Treatment at a Safety Net Hospital.
    Journal of acquired immune deficiency syndromes (1999), 2022, 11-01, Volume: 91, Issue:3

    Topics: Encephalitis; Financial Stress; HIV Infections; Humans; Pharmaceutical Preparations; Pyrimethamine;

2022
Unusual Toxoplasma infection of the eye and central nervous system in an HIV-positive patient.
    Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne, 2022,Fall, Volume: 71, Issue:3

    Topics: Adult; Antibodies, Protozoan; Blindness; Central Nervous System; HIV Infections; Humans; Immunoglobu

2022
"They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali.
    Maternal and child health journal, 2020, Volume: 24, Issue:1

    Topics: Adult; Antimalarials; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; Health Knowl

2020
Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa.
    Malaria journal, 2017, 10-06, Volume: 16, Issue:1

    Topics: Africa South of the Sahara; Antimalarials; Coinfection; Cost-Benefit Analysis; Drug Combinations; Fe

2017
Trends in comparative efficacy and safety of malaria control interventions for maternal and child health outcomes in Africa: a study protocol for a Bayesian network meta-regression exploring the effect of HIV and malaria endemicity spectrum.
    BMJ open, 2019, 02-22, Volume: 9, Issue:2

    Topics: Africa South of the Sahara; Antimalarials; Bayes Theorem; Child Health; Child, Preschool; Clinical P

2019
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.
    The Journal of infectious diseases, 2013, Volume: 208, Issue:6

    Topics: Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Infections; H

2013
Malaria in pregnancy: challenges for control and the need for urgent action.
    The Lancet. Global health, 2015, Volume: 3, Issue:8

    Topics: Africa South of the Sahara; Antimalarials; Chemoprevention; Comorbidity; Drug Combinations; Early Di

2015
Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region.
    The American journal of tropical medicine and hygiene, 2017, Jan-11, Volume: 96, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; HIV In

2017
Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine: More Than Just an Antimalarial?
    The American journal of tropical medicine and hygiene, 2017, Jan-11, Volume: 96, Issue:1

    Topics: Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnancy Comp

2017
Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11

    Topics: Adult; Alleles; Animals; Antimalarials; Base Sequence; Child, Preschool; DNA Primers; DNA, Protozoan

2008
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda.
    Malaria journal, 2009, Nov-14, Volume: 8

    Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Cross-Sectional Studies; Drug Combinati

2009
Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.
    Maternal and child health journal, 2011, Volume: 15, Issue:4

    Topics: Africa; Antimalarials; Comorbidity; Drug Combinations; Drug Resistance; Female; HIV Infections; Huma

2011
Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.
    The Journal of infectious diseases, 2011, Feb-15, Volume: 203, Issue:4

    Topics: Adolescent; Adult; Anemia; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combination

2011
Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2011, Volume: 30, Issue:12

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretro

2011
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
    The Pan African medical journal, 2010, Volume: 7

    Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug

2010
Sulphadiazine-induced obstructive renal failure complicating treatment of HIV-associated toxoplasmosis.
    International journal of STD & AIDS, 2012, Volume: 23, Issue:3

    Topics: Antiprotozoal Agents; Fluid Therapy; HIV Infections; Humans; Middle Aged; Nephrostomy, Percutaneous;

2012
[Clinical and therapy features of ocular toxoplasmosis in patients with HIV-AIDS infection].
    Oftalmologia (Bucharest, Romania : 1990), 2002, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Folic Ac

2002
Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients.
    The Journal of infectious diseases, 2003, Oct-01, Volume: 188, Issue:7

    Topics: Adolescent; Adult; Aged; Alleles; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bronchoalveolar Lav

2003
Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART.
    Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:5

    Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Chromatography, Gas; Chromatography, High

2004
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:11

    Topics: Adult; Amino Acid Sequence; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cloning, Molecular;

2004
Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation.
    The Journal of infection, 2006, Volume: 52, Issue:2

    Topics: Adult; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Female; Fetal Blood; HIV Infections; Hu

2006
Impact of chloroquine on viral load in breast milk.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; Antimalarials; Breast Feeding; CD4 Lymphocyte Count; Chloroquine; Drug Combi

2006
Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles.
    The Journal of infectious diseases, 2006, Jul-15, Volume: 194, Issue:2

    Topics: Alleles; Animals; Antimalarials; Drug Combinations; Drug Resistance; Folic Acid Antagonists; Genotyp

2006
Protecting pregnant women from malaria in areas of high HIV infection prevalence.
    The Journal of infectious diseases, 2006, Aug-01, Volume: 194, Issue:3

    Topics: Africa South of the Sahara; Antimalarials; Chemoprevention; Disease Outbreaks; Drug Combinations; Fe

2006
Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:3

    Topics: HIV Infections; Humans; Malaria, Falciparum; Pyrimethamine; Sulfadoxine; Sulfamethoxazole; Trimethop

2006
Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members.
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:3

    Topics: Animals; Antimalarials; Cohort Studies; Drug Combinations; Drug Resistance; Family; HIV Infections;

2006
HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
    The Journal of infectious diseases, 2006, Dec-01, Volume: 194, Issue:11

    Topics: Adult; Anemia; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; Fever; HIV Infections

2006
Subclinical Plasmodium falciparum infection and HIV-1 viral load.
    Emerging infectious diseases, 2007, Volume: 13, Issue:2

    Topics: Adult; Animals; Antimalarials; Drug Combinations; HIV Infections; HIV-1; Humans; Infant; Kenya; Mala

2007
Malaria treatment efficacy among people living with HIV: the role of host and parasite factors.
    The American journal of tropical medicine and hygiene, 2007, Volume: 77, Issue:4

    Topics: Adolescent; Adult; Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Dru

2007
Cerebral toxoplasmosis in childhood and adult HIV infection treated with 1-4 hydroxynaphthoquinone and rapid desensitization with pyrimethamine.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Atovaquone; Child; Desensitizati

1995
[Porphyria cutanea tarda and human immunodeficiency virus infection. Apropos of 2 further cases].
    Revista clinica espanola, 1994, Volume: 194, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Drug Therapy, Combination; HIV Infectio

1994
Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:5

    Topics: Adult; Aged; Dapsone; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Phenotyp

1994
[Clarithromycin in the treatment of cerebral toxoplasmosis associated with HIV infection].
    Revista clinica espanola, 1993, Volume: 192, Issue:9

    Topics: Adult; Clarithromycin; Drug Therapy, Combination; Female; HIV Infections; Humans; Pyrimethamine; Tox

1993
[Toxic dermatitis caused by pyrimethamine in patients with acquired immunodeficiency virus infection].
    Presse medicale (Paris, France : 1983), 1995, Nov-25, Volume: 24, Issue:36

    Topics: Adult; Anti-Infective Agents; Drug Eruptions; HIV Infections; Humans; Male; Pyrimethamine

1995
[Cerebral toxoplasmosis in patients with human immunodeficiency virus (HIV) infection. Clinico-radiological and therapeutic aspects in 63 patients].
    Anales de medicina interna (Madrid, Spain : 1984), 1996, Volume: 13, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clind

1996
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    Controlled clinical trials, 1995, Volume: 16, Issue:6

    Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitorin

1995
Persistent diarrhea caused by Isospora belli: therapeutic response to pyrimethamine and sulfadiazine.
    Diagnostic microbiology and infectious disease, 1996, Volume: 26, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Infective Agents; Antitrichomonal Agents; Diarrhea

1996
Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, Jun-01, Volume: 15, Issue:2

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Anti-Infective Agents; Antidotes; Dideoxynucleosides;

1997
Oral manifestations of toxic epidermal necrolysis (TEN) in patients with AIDS: report of five cases.
    Oral diseases, 1998, Volume: 4, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age

1998
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
    The American journal of tropical medicine and hygiene, 1998, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum

1998
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
    The American journal of tropical medicine and hygiene, 1998, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum

1998
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
    The American journal of tropical medicine and hygiene, 1998, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum

1998
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
    The American journal of tropical medicine and hygiene, 1998, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum

1998
Clinical microbiological case: visual problems in an HIV-positive patient.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2001, Volume: 7, Issue:11

    Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Antiretroviral Therapy,

2001
Ocular toxoplasmosis in human immunodeficiency virus-infected patients.
    American journal of ophthalmology, 1992, Aug-15, Volume: 114, Issue:2

    Topics: Adult; Aged; Clindamycin; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Follow-Up S

1992
Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.
    The Clinical investigator, 1992, Volume: 70, Issue:6

    Topics: Adult; Aerosols; Aged; CD4-Positive T-Lymphocytes; Drug Combinations; Encephalitis; Female; HIV Infe

1992
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
    AIDS (London, England), 1991, Volume: 5, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Brain Diseases; Dapsone; Drug Administration Schedule; Drug Ther

1991
Infectious disease emergencies in persons with HIV/AIDS: an update.
    The Journal of the Arkansas Medical Society, 1990, Volume: 87, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Clindamycin; Communicable Diseases; Fluconazole;

1990